ArticleCMAJ open
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.
Abstract read
In one paragraph
Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.BMC infectious diseases · 2017Trial
- Direct-Acting Antivirals and Risk of Hepatitis C Extrahepatic Manifestations.JAMA network open · 2025Article
- The Impact of New Direct-Acting Antiviral Therapy on the Prevalence and Undiagnosed Proportion of Chronic Hepatitis C Infection in Alberta: A Model-Based Analysis.Canadian liver journal · 2025Article
- Hepatitis C Virus Infection in Europe.Pathogens (Basel, Switzerland) · 2024Review
- Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.Lancet regional health. Americas · 2024Article
- Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.Canadian liver journal · 2023Article
- Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.Addiction (Abingdon, England) · 2023Article
- The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.PloS one · 2023Article
- Women in the 2019 hepatitis C cascade of care: findings from the British Columbia Hepatitis Testers cohort study.BMC women's health · 2021Article
- The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.PloS one · 2021Article
- Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Differences among hepatitis C patients seen in community and specialist outpatient care settings.Canadian liver journal · 2020Article
- Strategies to achieve population control of HCV infection: results of a multidisciplinary focus group.Canadian liver journal · 2020Article
- HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.BMC infectious diseases · 2019Article
- Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.Liver international : official journal of the International Association for the Study of the Liver · 2019Article
- Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?Canadian liver journal · 2019Review
- Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.Journal of the International AIDS Society · 2018Article
- Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia.Harm reduction journal · 2018Article
- A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.Harm reduction journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Alison D MarshallThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Sahar SaeedThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Lisa BarrettThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Curtis L CooperThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Carla TreloarThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Julie BruneauThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Jordan J FeldThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Lesley GallagherThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Marina B KleinThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Mel KrajdenThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Naglaa H ShoukryThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Lynn E TaylorThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Jason GrebelyThe Kirby Institute (Marshall, Grebely), UNSW Australia, Sydney, Australia; Department of Epidemiology, Biostatistics and Occupational Health (Saeed), McGill University, Montréal, Que.; Faculty of Medicine (Klein), McGill University, Montréal, Que.; Faculty of Medicine (Barrett), Dalhousie University, Halifax, NS; Department of Medicine (Cooper), University of Ottawa, Ottawa, Ont.; Centre for Social Research in Health (Treloar), UNSW Australia, Sydney, Australia; Centre de recherche du Centre hospitalier de l'Université de Montréal (Bruneau, Shoukry), Montréal, Que.; Liver Centre (Feld), Toronto Western Hospital, University Health Network/University of Toronto, Toronto, Ont.; Vancouver Coastal Health (Gallagher); BC Centre for Disease Control (Krajden), Vancouver, BC; Department of Medicine (Taylor), Brown University, Providence, RI.
Canadian Network on Hepatitis C (CanHepC)
Funding
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7MNIAID NIH HHS P30 AI042853
Abstract
backgroundIn Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4 HCV direct-acting antivirals in Canada.
methodsWe reviewed the reimbursement criteria for simeprevir, sofosbuvir, ledipasvir
resultsOverall, 85%-92% of provinces/territories limited access to patients with moderate fibrosis (Meta-Analysis of Histologic Data in Viral Hepatitis stage F2 or greater, or equivalent). There were no drug and alcohol use restrictions; however, several criteria (e.g., active injection drug use) were left to the discretion of the physician. Quebec did not reimburse simeprevir and sofosbuvir for people coinfected with HIV; no restrictions were found in the remaining jurisdictions. Prescriber type was restricted to specialists in up to 42% of provinces/territories.
interpretationThis review of criteria of reimbursement of HCV direct-acting antivirals in Canada showed substantial interjurisdictional heterogeneity. The findings could inform health policy and support the development and adoption of a national HCV strategy.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.